Abstract: This disclosure relates to an enhanced molecular-targeted approach that targets treatment-induced or native hypoxia present within cancers, specifically, but not limited to the treatment of metastatic prostate cancer with androgen deprivation therapy, such as anti-androgens. The disclosure describes the utility of combined inhibition of IL-8 and VEGF signalling to effect a combined therapeutic response of malignant disease, which is magnified under conditions of hypoxia. Thus, provided is a pharmaceutical combination for use in the treatment of cancer, the pharmaceutical combination comprising: a vascular endothelial growth factor (VEGF) signalling inhibitor; and an interleukin-8 (IL-8) signalling inhibitor; wherein said use comprises administration of the pharmaceutical combination to a patient receiving an anti-cancer therapy.

Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.

Abstract: A sheet having a supplemental label according to an embodiment includes a presentation portion having a print receptive front face and a coupling portion coupled to the presentation portion. The coupling portion is a transparent composite film made of an upper film, a repositional adhesive, a release agent, another layer of film, and an adhesive which is joined to a substrate such as paper or other print receptive media.

Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.

Abstract: Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.

Abstract: The present application discloses methods for treating a multi-level spinal deformity. The methods may include inserting a tether in a minimally-invasive manner through an entrance incision. The tether is moved along the spine and positioned to reduce and/or eliminate the deformity. Once the tether is positioned along the spine, the tether may be secured to the vertebral members. In one embodiment, the tether includes a rigid section and a flexible section. The tether may be positioned within the spine with the rigid section extending along a first length of the spine and the flexible section extending along a second length of the spine. The different sections provide different corrective forces to the spine to reduce and/or eliminate the spinal deformity. In one embodiment, the rigid section extends along an apex of the spinal deformity.

Abstract: The present application discloses methods for treating a multi-level spinal deformity. The methods may include inserting a tether in a minimally-invasive manner through an entrance incision. The tether is moved along the spine and positioned to reduce and/or eliminate the deformity. Once the tether is positioned along the spine, the tether may be secured to the vertebral members. In one embodiment, the tether includes a rigid section and a flexible section. The tether may be positioned within the spine with the rigid section extending along a first length of the spine and the flexible section extending along a second length of the spine. The different sections provide different corrective forces to the spine to reduce and/or eliminate the spinal deformity. In one embodiment, the rigid section extends along an apex of the spinal deformity.

Abstract: There is described compounds for use in therapy, said compounds being defined by Formula (1): There is also described an anti-proliferative composition comprising one or more compounds according to Formula (1), and a method of treatment of neoplasia comprising the administration of such a compound or composition.

Abstract: Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.

Abstract: The present application discloses methods for treating a multi-level spinal deformity. The methods may include inserting a tether in a minimally-invasive manner through an entrance incision. The tether is moved along the spine and positioned to reduce and/or eliminate the deformity. Once the tether is positioned along the spine, the tether may be secured to the vertebral members. In one embodiment, the tether includes a rigid section and a flexible section. The tether may be positioned within the spine with the rigid section extending along a first length of the spine and the flexible section extending along a second length of the spine. The different sections provide different corrective forces to the spine to reduce and/or eliminate the spinal deformity. In one embodiment, the rigid section extends along an apex of the spinal deformity.

Abstract: Push button controlled wireless transmitters send digitally encoded signals to a plug-in receiver/signaling device. The receiver/signaling device has a microprocessor suitably programmed to respond to signals from a transmitter bearing the discrete address of the receiver, and to decode a transmitter identification code. Thereupon the microprocessor supplies an audio output circuit with signals to simulate selectively mechanical front or back door chimes, and supplies signals to energize a strobe lamp to emit bursts of multiple flashes, the number of flashes in a burst identifying the specific transmitter, whereby a person with a hearing deficiency is informed as to which transmitter is being actuated.